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Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated motor 
and/or sensory disorder of the peripheral nerves which presents in various forms, resulting in 
functional neurological deficits. The prevalence of CIDP is low, of around 5 per 100,000 (1) 
but it is a treatable disorder which responds to treatment, amongst which corticosteroids, 
intravenous immunoglobulins (IVIg) and plasma exchanges (PE). The issue around 
evaluating effects of the treatment of CIDP is of great importance, both in avoiding 
deterimental indesirable effects as well as ensuring optimum cost-to-benefit ratio.  
As a result, effective, reliable and reproducible ways of assessing the benefit of treatment, or 
the lack of it, are essential in clinical practice. In its typical form, CIDP presents with 
proximal and distal weakness of the 4 limbs. Sensory loss to large fibre modalities 
predominate. Motor deficits frequently represent the basis of disability. The evaluation of 
treatment effects has for many clinicians, been reliant on Medical Research Council (MRC) 
scores of groups of muscles, pre- and post-therapy. However, in sensory predominant forms 
strength scores are unhelpful. Use of disability measures are often not systematic and 
individualised goals, if used, may not infrequently be based on imprecise subjective 
descriptions, sometimes in retrospect. IVIg has not been demonstrated as effective on 
improving strength scores in metaanlyses of clinical trials performed, whereas they have been 
shown to improve disability scores. Different scales were however used in different trials and 
their clinical equivalence is not established. Transformation of various scales in a modified 
Rankin Scale equivalent allowed to demonstrate benefit from 3 pooled studies of 84 
participants in the last Cochrane review (2). 
Disability scales are often considered by clinicians mainly as research tools and their 
implementation in day-to-day practice is variable. There are many reasons for this, including 
lack of time for detailed assessments, lack of familiarity with scales, as well as focus on 
traditional methods of evaluation which often include priority given to subjective patient 
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descriptions. Also, the simple lack of interest by treating physicians, is a non-negligible 
factor. In recent years, emphasis has been put on the use of meaningful assessment tools, 
albeit essentially in the research arena, with increasing evidence of the inappropriateness of 
traditonal MRC scores in the first instance. A new Rasch-built MRC grading has been 
proposed (3) but its clinical usage and uptake, has not been evaluated. The INCAT 
(Inflammatory Neuropathy Cause and Treatment Group) scale, consisting of an upper and a 
lower limb disability level component, represents a method used by many in practice (4). A 
newer version, the ONLS (Overall Neuropathy Limitation Scale), consisting of a slight 
variation of the leg score, has, similarly, been adopted by others (5). Despite poor content and 
structural validity, these scales are considered reliable and responsive (6). The minimum 
detectable change with the scale was however found greater than the minimal clinically 
important difference (MCID) which suggests suboptimal sensitivity to detect improvement in 
some subjects, compounded by low emphasis on proximal upper limb function and stamina-
related tasks (6). In more recent years, a Rasch-built Overall Disability Scale (RODS) for 
Guillain-Barré syndrome (GBS), CIDP and gammopathy-related polyneuropathy has been 
developed, with construction of a 24-item scale consisting of tasks of increasing difficulty, 
with a conversion into a centile metric score, varying from 0 (greatest activity and social 
participation limitation) to 100 (no activity and social participation limitation) (7). Compared 
to the ONLS, this “Inflammatory RODS” (“I-RODS”) offered assessment of a wider range of 
item difficulties, and therefore evaluation of patients of different ability. Still more recently, 
grip strength, using a Martin vigorimeter or Jamar dynamometer, has been described as a 
reliable measure of treatment effect in CIDP (8), and correlations have been found with the 
ONLS and I-RODS (9, 10).  
The practical usage of disability scales in patients with CIDP is more often than not straight 
forward. Scales such as the INCAT and ONLS offer rapid evaluation of change, with 
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minimal examiner training and take a very short time to administer. A clinician familiar with 
the scale is usually able to score an individual patients in a few minutes. Similarly, the I-
RODS scale, although lengthier, can, with adequate directives to patients, rapidly and easily 
be completed by themselves prior to, or at, attendance, or be evaluated similarly within a few 
minutes by the clinician. Grip strength measurements also represent a very convenient and 
and quick evaluation method, which in view of recent studies, may in certain instances even 
supersede above-mentioned scales.  
Difficulties in the use of these assessment tools are however real for the clinician. The 
INCAT and ONLS may not detect meaningful change in an improved patient and may not 
ascertain important deficits preventing repetitive movements or tasks. The I-RODS may not 
be culturally adapted to all subjects and may entail uncetainties and confusion for individual 
patients, for example, in separating what, for some individual items, is “difficult” or “not 
difficult”. Furthermore, the impact of the repetitive nature of such full, all-item assessments 
on responses provided has not been studied, particularly in patients who deem themselves 
stable, although this may result in bias. The use of these scales is also complicated by 
associated conditions and for example, concurrent rheumatological, cardiovascular or 
respiratory disease, and even potentially more so, depressive illness, can make scores very 
challenging for adequate interpretation. Delineating what is purely related to the neuropathy, 
often as a result, requires in clinical practice, more than these scores. Individual patients’ 
level of functioning may otherwise also vary considerably. In the very active subject, the 
“ability to run” or “walk for a kilometre” may not reflect the actual limitation experienced, 
and it is not uncommon to hear descriptions of disabling deficits preventing more demanding 
tasks which they previously performed without problem. Similarly, in patients severely 
disabled at baseline, recovering upper limb ability allowing to write, turn pages of a book, use 
a spoon to feed, or use a mobile phone, tablet, or remote control, can be of paramount 
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importance to quality of life. These are however not precisely considered in the items of 
existing scales for CIDP. Disability scores, in clinical practice may not always fully replace 
for those reasons, the need for detailed history-taking and adequate questioning regarding 
most important functions for the individual at baseline, in comparison to pre-morbid state as 
well as with their current global impairment. Strength score testing as well as sensory, 
particulary propioceptive, examination remain similarly important to separate neurological 
deficits from those resulting from other causes. Further evaluations with ten-metre timed 
walks and 6-minute walking distance, may all represent potentially useful measures in 
selected cases. Tailoring the assessment to the needs of the patient is therefore essential in the 
task of monitoring patients with CIDP. 
Another important question when scales are used in CIDP is how much improvement is 
genuinely clinically meaningful? The answer to this remains also central to the issue of 
clinical monitoring as has major implications on subsequent therapeutic decisions. 
Traditionally, an improvement of MRC scores by a total of 2 points in at least 2 muscles was 
often considered as a marker of objective improvement. The recent study on the poor 
reliability of the MRC scale (3) casts significant doubt on such a definition. The use of 
disability scales themselves require establishing clinically meaningful cut-offs for change, to 
define improvement or deterioration. The concept of MCID appears relevant and fundamental 
in clinical practice as much as research, although is commonly overlooked. The complexity 
surrounding the MCID, which also depends on patients’ perspectives of the relevance of 
individual scale items as well on scale dynamics in relation to disease subtype (particularly 
with the heterogeneity of CIDP), makes it difficult in practice to agree on what score change 
is meaningful (11). This in turn leads to situations in clinical practice which are difficult to 
interpret, and still more difficult to act upon. An change of one point on the ONLS/INCAT 
has been found to correspond to one of about 4 points on the I-RODS (12). A score 
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improvement from 3 to 2 for the arm component of the ONLS, with the patient describing 
being able to do buttons and zips with difficulty again, without any other change, may result 
in treatment continuation, possibly at high doses. How relevant this may be to the subject’s 
quality of life could be detable. This would be different from being able to walk 
independently again from having had to use a stick (similar one point improvement, of the leg 
score from 3 to 2). In the same way, although more extensive, the I-RODS may pose similar 
issues, with a 4-point improvement as a result of feeling less difficuly making a sandwich, 
washing up, moving a chair or throwing a ball (if the need ever occurred for either!), having 
less impact in the eyes of many active patients, than recovering the ability, albeit with 
difficulty, to run, dance, climb stairs, or carry a heavy load. Therapeutic decisions made on 
the basis of such similar point improvements, without consideration of their weight in terms 
of quality of life amelioration in the individual, is problematic. Lack of clear indication, in the 
first place, of the amplitude of change to be considered in absolute terms, may make this task 
undoable. A cut-off of 8 kPa has been sugested as clinically-meaningful with Martin 
vigorimeter grip strength measurements (8). However its application in practice remains 
uncertain and debatable. Still more uncertain are the meaningful amplitude of improvements 
of timed 10-metre walks or 6-minute walks with relevance to individual patients’ deficits and 
functional needs to improve their quality of life in CIDP, although cut-offs have been 
proposed for other disorders (13).  
Despite their limitations, available disability scales offer the best possible method for 
objective assessment of patients with CIDP. Given the high cost of IVIg and PE and the side-
effects that may occur with any treatment, it is imperative that evaluation of treatment benefit 
is based on as reliable and reproducible methods as possible. Disability scales appear to 
clearly offer significant advantages to make this process more consistent and achievable in 
practice. Besides issues directly related to the scales themselves, many challenges however 
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remain, including the problems of concurrent illnesses, to be separated from purely 
psychological factors, which undeniably also play a role in the use of any scale. It appears 
likely that the available scales, although very useful, may frequently be insufficient and that 
their use should be part of a wider more detailed assessment, rather than represent it in 
totality. Instead of simpler, shorter and exclusively patient-reported outcomes as suggested by 
recent research and which will be approriate and useful for future trials, the reality of clinical 
day-to-day practice may in fact, require more detailed and lengthier evaluations. These 
should ideally be tailored to each subject, given the complexity of each individual case and, 
especially, the importance of making the best management decision for each patient. 
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